Pure Biologics Spólka Akcyjna
PUR.WA · WSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | PLN 0 | PLN 0 | PLN 1 | PLN 0 |
| % Growth | -100% | -85.6% | 160.6% | – |
| Cost of Goods Sold | PLN 0 | PLN 3 | PLN 6 | PLN 4 |
| Gross Profit | -PLN 0 | -PLN 3 | -PLN 5 | -PLN 4 |
| % Margin | – | -2,709.5% | -816.8% | -1,585.4% |
| R&D Expenses | PLN 0 | PLN 0 | PLN 24 | PLN 21 |
| G&A Expenses | PLN 0 | PLN 7 | PLN 8 | PLN 4 |
| SG&A Expenses | PLN 15 | PLN 7 | PLN 8 | PLN 4 |
| Sales & Mktg Exp. | PLN 0 | PLN 0 | PLN 0 | PLN 0 |
| Other Operating Expenses | -PLN 3 | PLN 23 | PLN 11 | PLN 3 |
| Operating Expenses | PLN 12 | PLN 29 | PLN 19 | PLN 6 |
| Operating Income | -PLN 12 | -PLN 32 | -PLN 25 | -PLN 10 |
| % Margin | – | -33,387.4% | -3,720.4% | -4,126.8% |
| Other Income/Exp. Net | -PLN 1 | -PLN 4 | -PLN 1 | -PLN 1 |
| Pre-Tax Income | -PLN 13 | -PLN 36 | -PLN 26 | -PLN 12 |
| Tax Expense | PLN 0 | PLN 0 | PLN 1 | PLN 1 |
| Net Income | -PLN 19 | -PLN 36 | -PLN 26 | -PLN 13 |
| % Margin | – | -37,572.6% | -3,983.7% | -5,146.1% |
| EPS | -3.78 | -11.19 | -11.87 | -5.88 |
| % Growth | 66.2% | 5.7% | -101.9% | – |
| EPS Diluted | -3.78 | -11.19 | -11.87 | -5.88 |
| Weighted Avg Shares Out | 5 | 3 | 2 | 2 |
| Weighted Avg Shares Out Dil | 3 | 3 | 2 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | PLN 0 | PLN 0 | PLN 0 | PLN 0 |
| Interest Expense | PLN 1 | PLN 4 | PLN 0 | PLN 0 |
| Depreciation & Amortization | PLN 0 | PLN 6 | PLN 2 | PLN 3 |
| EBITDA | -PLN 12 | -PLN 26 | -PLN 23 | -PLN 9 |
| % Margin | – | -27,449.5% | -3,440.6% | -3,392.9% |